To access the live webcast, please visit Biogen
's Investors section at www.biogen.com/investors.
Q2 2019 Revenues Increased 8% to $3.6 Billion
Piper Jaffray analyst Christopher Raymond is "incrementally cautious" on Biogen
(BIIB) shares after AbbVie (ABBV) announced its anti-tau antibody Phase 2 trial in progressive supranuclear palsy was discontinued for futility.
M2 EQUITYBITES-April 23, 2019-Nightstar Therapeutics, Biogen
Bidco Clear US Antitrust Hurdle in merger
has entered a share purchase agreement to acquire the shares of Biogen
's subsidiary with biologics manufacturing operations in Hillerod, Denmark, for as much as $890 million in cash, subject to contractual terms.
(Nasdaq: BIIB), a US-based multinational biotechnology company, announced yesterday that it has entered into a share purchase agreement with Fujifilm Corporation (Fujifilm).
Global Banking News-March 12, 2019-Fujifilm to acquire USD890m Biogen
HillerAd biologics manufacturing site
Neuroscience company Biogen
Inc (Nasdaq: BIIB) and Skyhawk Therapeutics Inc (Skyhawk) disclosed on Friday that the companies have entered into a strategic collaboration agreement, in which Skyhawk's SkySTAR technology platform will be used to help discover novel small molecule treatments for neurological patients.
and Ionis Pharmaceuticals have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases.
There will be no change to the manufacturing or logistic systems, and Biogen
Japan books sales of the products.
Vounatsos joined Biogen
last April after 20 years of experience at Merck & Co.